Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T23:31:00.928Z Has data issue: false hasContentIssue false

Debate 17A - When is the Best Time to Use PARP Inhibitors for Maintenance?

Front-line

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

By
Duaa H. Al-Rawi ,
Karen Cadoo  and
Roisin O’Cearbhaill
Edited by
Dennis S. Chi ,
Nisha Lakhi  and
Nicoletta Colombo
Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

The development and use of Poly(ADP-ribose) polymerase inhibitors (PARPi) in advanced ovarian cancer (OC) have been an incredible clinical breakthrough. PARPi are FDA-approved as front-line maintenance for BRCA1-/2- associated (olaparib or niraparib), homologous recombination deficient (HRD) (niraparib or olaparib with bevacizumab), and homologous recombination proficient (HRP) (niraparib) advanced-stage high-grade ovarian cancer (HGOC). Along with a third PARPi, rucaparib, they are also approved following recurrence as both maintenance and treatment. Here we advocate for PARPi as front-line maintenance for BRCA1-/2- associated (germline or somatic) and HRD tumors. We also discuss our recommendations for patients with HRP tumors.

Type
Chapter
Information
50 Big Debates in Gynecologic Oncology , pp. 95 - 97
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Moore, K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495–2505.CrossRefGoogle ScholarPubMed
Ray-Coquard, I, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416–2428.CrossRefGoogle ScholarPubMed
Gonzalez-Martin, A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391–2402.CrossRefGoogle ScholarPubMed
Poveda, A, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):620–631.CrossRefGoogle Scholar
Moore, KN, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636–648.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×